FDA approves new diagnostic imaging agent to detect recurrent prostate cancer

You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

 

05/27/2016 11:27 AM EDT

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.

.


This email was sent to bsamad2007.adnan@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) Powered by GovDelivery

Comments

Popular Posts

You’re four weeks away from more followers 📱

We have Your e-Wallet ready. Claim in 3hrs

Beneficiary countersignature modification

Engr Suman wants to be friends on Facebook

Reduced Payment!.

Your order requires immediate confirmation.

Commissions Successfully

Fwd: Claim "Climate law & governance" for your profile